4min chapter

Breakpoints cover image

#60 – Going MAD for Non-COVID ID Literature: A Year in Review LIVE from MAD-ID

Breakpoints

CHAPTER

The Anti Fungal Pipeline in Drugs

The next major trial that came out was the phase three randomized double blind non inferiority trial of pose a console versus worry connozzle for the primary treatment of invasive aspergiliosis. We developed 575 patients from 26 countries with proven probable or suspected invasive as pergiliosis and we ended this to only patients with proven or probable disease it was 19% in each arm. Treatment related adverse events were greater in the worry Connozzle arm 40% versus 30%. And these were largely driven by neuro toxicity so hallucinations and things like that which I think we've all seen in our patients on worryConnie. So overall what we need to know about this trial is it's a

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode